MedPath

Enveric Biosciences Secures Patent for Novel EVM401 Compounds Targeting Mental Health Treatment

• Enveric Biosciences has obtained a U.S. patent for its innovative EVM401 series of compounds, expanding its intellectual property portfolio in mental health therapeutics.

• The newly patented compounds are designed to target neuropsychiatric conditions through novel mechanisms, potentially offering new treatment options for patients with mental health disorders.

• This patent protection strengthens Enveric's position in the psychedelic medicine space and provides market exclusivity for their therapeutic development program.

Enveric Biosciences has achieved a significant milestone with the United States Patent and Trademark Office (USPTO) granting patent protection for its novel EVM401 series of compounds, marking a crucial advancement in the development of innovative mental health therapeutics.
The patent encompasses a broad range of novel chemical entities designed to address various neuropsychiatric conditions, reinforcing Enveric's commitment to developing next-generation treatments for mental health disorders. This intellectual property protection secures the company's position in the competitive psychedelic medicine landscape.

Strategic Expansion of Drug Development Portfolio

The EVM401 series represents a strategic expansion of Enveric's drug development pipeline, building upon the company's expertise in developing novel compounds for mental health conditions. The patent protection extends to multiple compound variations and their therapeutic applications, providing Enveric with significant market exclusivity.
"This patent grant validates our innovative approach to developing new therapeutic options for patients suffering from mental health conditions," states a senior representative from Enveric Biosciences. "The EVM401 series embodies our commitment to advancing the field of neuropsychiatric medicine through novel chemical entities."

Therapeutic Potential and Development Strategy

The protected compounds are being developed to target specific neurological pathways associated with various mental health disorders. Enveric's research suggests these novel molecules may offer improved therapeutic profiles compared to existing treatments, potentially providing better outcomes for patients.
The company plans to advance the most promising candidates from the EVM401 series through preclinical studies, with the goal of identifying lead compounds for clinical development. This systematic approach aligns with Enveric's mission to bring innovative therapeutic solutions to patients while building long-term value for stakeholders.

Market Impact and Future Directions

This patent grant strengthens Enveric's competitive position in the rapidly evolving psychedelic medicine market. The company's expanding intellectual property portfolio provides a solid foundation for future partnerships and development opportunities in the mental health therapeutics space.
The protected technology platform may enable the development of multiple drug candidates, each targeting specific aspects of mental health conditions. This versatility could lead to a diverse pipeline of therapeutic options, addressing various unmet needs in neuropsychiatric medicine.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ensysce Biosciences Advances Abuse-Resistant Opioids PF614 and PF614-MPAR Towards Market

Ensysce Biosciences reports significant progress in its clinical programs for PF614 and PF614-MPAR, designed for safer pain relief with reduced abuse potential.
PF614, an extended-release oxycodone, is set to begin Phase 3 trials in Q2 2025, evaluating its efficacy in post-abdominoplasty pain management.

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).
Crinecerfont is designed to reduce elevated androgen levels in individuals with CAH, addressing a critical unmet need in current treatment.

Enveda Biosciences Secures $130 Million to Advance AI-Powered Drug Discovery

Enveda Biosciences has raised $130 million in a Series C funding round to advance its AI-driven drug discovery platform and clinical pipeline.
The funding will support clinical trials for multiple drug candidates, including ENV-294, an oral anti-inflammatory agent for atopic dermatitis.

enVVeno Medical Seeks FDA Approval for VenoValve in Severe Deep Venous CVI

enVVeno Medical has submitted its Premarket Approval (PMA) application to the FDA for VenoValve, a device to treat severe deep venous Chronic Venous Insufficiency (CVI).
The VenoValve has breakthrough device designation, and four of five PMA modules are approved, with clinical data from the SAVVE trial under review.

enVVeno Medical Seeks FDA Approval for VenoValve and Completes enVVe Study

enVVeno Medical has submitted its PMA application to the FDA for VenoValve, a breakthrough device for severe deep venous Chronic Venous Insufficiency (CVI).
The FDA is expected to make a decision on VenoValve in the second half of 2025, potentially offering a new treatment for 2.5 million U.S. candidates.

enVVeno Medical Seeks FDA Approval for VenoValve in Severe Chronic Venous Insufficiency

enVVeno Medical has submitted its Premarket Approval (PMA) application to the FDA for VenoValve, a surgical replacement venous valve.
The VenoValve is intended for treating severe deep venous Chronic Venous Insufficiency (CVI), a condition affecting approximately 2.5 million people in the U.S. annually.

Enveric Biosciences Advances EB-003 for Mental Health Disorders, Eyes 2025 IND Filing

Enveric Biosciences is progressing EB-003, a neuroplastogenic molecule, for treating mental health disorders without hallucinogenic effects.
Preclinical data confirms EB-003's oral bioavailability and brain penetration, targeting serotonergic receptors with minimal off-target interactions.

Enveda's AI-Driven Natural Product Candidate ENV-294 Enters Phase I for Atopic Dermatitis

Enveda's ENV-294, a novel oral anti-inflammatory agent derived from nature using AI, has entered Phase I clinical trials for atopic dermatitis and other inflammatory conditions.
The FDA has cleared the IND application for ENV-294, which has shown robust efficacy and high safety margins in preclinical studies.

Iterum Therapeutics Receives U.S. Patent Allowance for Oral Sulopenem Combination Therapy

Iterum Therapeutics has received a Notice of Allowance from the USPTO for a patent covering oral sulopenem with probenecid, enhancing its patent protection.
The patent, once issued, will protect the combination of sulopenem etzadroxil and probenecid for treating multiple diseases, including uncomplicated urinary tract infections, until at least 2039.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy